Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
about
PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.Fulvic acid attenuates homocysteine-induced cyclooxygenase-2 expression in human monocytesCharacterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy.Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer's Disease: Comparison and Contrast with Microtubule-Associated Protein Tau"Tau oligomers," what we know and what we don't know.Tau oligomers in cerebrospinal fluid in Alzheimer's disease.Familial Alzheimer's disease modelling using induced pluripotent stem cell technology.Cell-based Models To Investigate Tau Aggregation.Sodium humate accelerates cutaneous wound healing by activating TGF-β/Smads signaling pathway in ratsEmerging biomarkers and screening for cognitive frailty.The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios.Stages and conformations of the Tau repeat domain during aggregation and its effect on neuronal toxicityIridoids and Other Monoterpenes in the Alzheimer's Brain: Recent Development and Future Prospects.Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration.Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs.Phosphorylation, Dephosphorylation, and Multiprotein Assemblies Regulate Dynamic Behavior of Neuronal Cytoskeleton: A Mini-Review
P2860
Q35058484-61D1CFE2-7A17-4C67-B420-49745C9CB8E8Q35206746-66E35581-3179-432B-9ABF-6DA39C52F61EQ36963598-9C2208EA-66D9-44C5-B952-5C9114AD99F1Q37089388-5B1596DF-19C8-4CF7-A195-C06FC7D78DF8Q37467443-80A51C7A-05C1-4E2B-81EA-715D6A9E7DA0Q37733987-2968DDA3-BE81-4788-B6E8-6EFE7F2B7959Q38207606-3B2673E3-E42E-4AD4-BFC4-CFE3E05BBFCCQ38287992-74F6A04C-CFF1-44FE-A3D2-91B531322585Q38950546-F306CE2C-35D4-4CC7-AF04-BBBF49857698Q39161884-DD6CEBCE-9802-49D9-83BA-9A897171FBEAQ41892980-2E23C937-AF5E-4EEA-89C0-A7D735C641C8Q41984715-9C32D520-F84E-4E7C-AF1E-52A970ECC4ABQ47216965-FD0D2696-0D94-4981-B12D-0F74AF701F4DQ47345806-5B8122BA-E320-41A7-9E1E-C3F4A611459EQ52344625-9ADCB71B-A483-4FB2-B736-A2991F560E9DQ55093166-323CD7DA-16DD-4E32-BF7E-4B066D114DECQ57817550-70B75B6E-F976-4301-9FD9-5896B10D3F49
P2860
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
@en
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs.
@nl
type
label
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
@en
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs.
@nl
prefLabel
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
@en
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs.
@nl
P2860
P356
P1476
Tau oligomers as potential targets for Alzheimer's diagnosis and novel drugs
@en
P2093
Leonardo Guzmán-Martinez
Ricardo Benjamin Maccioni
P2860
P356
10.3389/FNEUR.2013.00167
P577
2013-10-28T00:00:00Z